Table 2.
Patients’ characteristics compared between the non-PF-ILD and PF-ILD groups.
| Non-PF-ILD n = 17 (56.7%) |
PF-ILD n = 13 (43.3%) |
P value | |
|---|---|---|---|
| Age (year) | 71 (22) | 73 (7) | 0.408 |
| Height (cm) | 160.5 (9.9) | 159.6 (10.8) | 0.621 |
| Body weight (kg) | 60.6 (18.5) | 50.7 (12.3) | 0.065 |
| Body mass index (kg/m2) | 23.6 (4.7) | 22.2 (3.1) | 0.022 |
| Sex, male [n (%)] | 10 (58.8) | 10 (76.9) | 0.44 |
|
Smoking status (n) Never/former/current |
3/13/1 | 3/10/0 | 1.00 |
| Serum KL-6 level (U/mL) | 1248 (1278) | 797 (735) | 0.113 |
| Serum LDH level (U/L) | 238 (73) | 241 (44) | 1.000 |
| Diagnosis of ILD (n) | 0.588 | ||
| IPF | 4 | 5 | |
| Fibrotic HP | 6 | 5 | |
| CTD-ILD | 7 | 3 | |
| SSc | 3 | 1 | |
| PM/DM | 3 | 1 | |
| SjS | 0 | 1 | |
| MCTD | 1 | 0 | |
| Chest HRCT pattern (n) | 0.196 | ||
| f-NSIP | 5 | 1 | |
| UIP | 12 | 12 | |
| %FVC predicted at diagnostic BF (%) | 78.1 (19.0) | 67.0 (7.8) | 0.022 |
| Relative %FVC change over 6 months (%) | 0.6 (12.0) | -13.0 (11.6) | < 0.001 |
| Treatment during FVC measurements | 0.762 | ||
| None | 9 | 10 | |
| PSL | 3 | 1 | |
| PSL + Tac | 1 | 1 | |
| Antigen avoidance | 3 | 1 | |
| Nintedanib | 1 | 0 |
BF bronchoscopy, CTD connective tissue disease, f-NSIP fibrotic nonspecific interstitial pneumonia, FVC forced vital capacity, HP hypersensitivity pneumonitis, HRCT high-resolution computed tomography, ILD interstitial lung disease, IPF idiopathic pulmonary fibrosis, KL-6 Krebs von den Lungen-6, LDH lactate dehydrogenase, MCTD mixed connective tissue disease, PF-ILD progressive fibrosing interstitial lung disease, PSL prednisolone, PM/DM polymyositis/dermatomyositis, SjS Sjögren’s syndrome, SSc systemic sclerosis, Tac tacrolimus, UIP usual interstitial pneumonia.
Data are expressed as medians (interquartile range) unless otherwise stated. Differences between two groups were evaluated by the Mann–Whitney U test and quantitative differences were tested by the Chi-squared test for goodness of fit or by Fisher’s exact test.